Is a booster dose of COVID-19 vaccines effective on newly dominant omicron subvariants among university students? Comparison between BA.1 and BA.2 dominancy - 19/07/23
, Yukiko Nakano, MD, PhD b, Atsuo Yoshino, MD, PhD a, Yoshie Miyake, MD, PhD a, Yuri Okamoto, MD, PhD aHighlights |
• | A booster dose effectiveness is remains unclear against Omicron BA.2 subvariant. |
• | Updating evidence for university students is essential to improve their vaccine acceptance. |
• | A booster dose reduced the infection rate of close contacts during BA.2 dominancy. |
• | Vaccine effectiveness tended to decrease in BA.2 dominancy than in BA.1 dominancy. |
Abstract |
Background |
Although the COVID-19 Omicron BA.1 subvariant was initially predominant, the BA.2 subvariant has now replaced it. Effectiveness of a booster dose vaccination for BA.2 remains unclear among university students.
Methods |
We enrolled 562 Japanese university students who became a close contact and underwent polymerase chain reaction testing. We compared infection rates and cumulative incidence rates of severe fever among the students according to the COVID-19 vaccine doses received between BA.1-dominant (January 1-March 31, 2022) and BA.2-dominant (April 1-July 31, 2022) periods.
Results |
Infection rates for BA.1 were 32% with 3 doses, 49% with 2 doses, and 68% in the unvaccinated (P = .008). The odds ratio (OR) for infection following 3 doses during BA.1 was 0.46 (95% confidence interval [CI] = 0.25-0.82, P = .009). Infection rates for BA.2 were 45% with 3 doses, 62% with 2 doses, and 64% in the unvaccinated (P = .02). The OR for infection following 3 doses during BA.2 was 0.50 (95% CI = 0.31-0.82, P = .006). Effectiveness of vaccine for BA.2 tended to decrease for both 3 (45% vs 32%, P = .06) and 2 doses (62% vs 49%, P = .07) compared with those for BA.1.
Conclusions |
Booster dose effectiveness tended to decrease but remained significant against BA.2 subvariant predominancy among Japanese university students.
Le texte complet de cet article est disponible en PDF.Key words : Close contact, University health care, Vaccine effectiveness
Plan
| Conflict of interest: None to report. |
Vol 51 - N° 8
P. 907-911 - août 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
